Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
Related Questions
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
What is your experience with transesophageal lung mass biopsies?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
Is there any antiresorptive therapy that you would be comfortable prescribing if the patient refuses to see a dentist for clearance and is at risk of skeletal-related events?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
Would you use consolidation immunotherapy after chemoradiation for patients with stage III NSCLC and EGFR amplification?
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
